Tempus AI (NASDAQ:TEM) Shares Gap Up – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $49.36, but opened at $55.98. Tempus AI shares last traded at $56.4130, with a volume of 4,514,591 shares traded.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Freedom Capital raised Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Needham & Company LLC reiterated a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research report on Friday, July 31st. Finally, Lake Street Capital downgraded Tempus AI to a “hold” rating in a research note on Monday, July 20th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $65.69.

Tempus AI Price Performance

The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The company’s 50 day moving average is $52.44 and its 200 day moving average is $51.21. The stock has a market cap of $12.03 billion, a price-to-earnings ratio of -46.28 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. The firm’s revenue was up 21.6% on a year-over-year basis. Research analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 132,591 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $6,577,839.51. Following the sale, the chief executive officer owned 2,098,130 shares of the company’s stock, valued at $104,088,229.30. The trade was a 5.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 7,927 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $56.00, for a total value of $443,912.00. Following the completion of the sale, the executive vice president owned 138,140 shares in the company, valued at approximately $7,735,840. This represents a 5.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 943,202 shares of company stock worth $46,417,587. Corporate insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Tempus AI by 8.7% during the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after acquiring an additional 817,014 shares in the last quarter. ARK Investment Management LLC raised its position in Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after acquiring an additional 381,816 shares during the last quarter. GC Wealth Management RIA LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $399,267,000. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. grew its position in shares of Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.